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The role of palliative care for people with neurological disease has been developing for over 50 
years, and was described from the early days of the modern hospice movement. This thesis con-
siders my papers and studies which have helped in establishing the need for palliative care, the 
involvement of specialist palliative care services, the effectiveness of palliative care for neurologi-
cal patients, the importance of complex decision making for this patient group and the 
development of guidelines, to enable care to be more widely established for patients and families.  
 
These papers have developed from the evidence from earlier research and the experience of hos-
pices and specialist palliative care teams and helped to encourage further research. They have 
been important in providing an evidence-base for neurological palliative care and supported a 
wider recognition of the role of palliative care for people with neurological disease. The research 
reported here demonstrates how the increasing collaboration between specialist palliative care 
services and neurology can result in improved care of patients with neurological disease, together 
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The aim of this commentary is to show how the research which I have undertaken, and the papers 
resulting from this, have helped in the development of palliative care for neurological disease, and 
in particular motor neurone disease (MND). The research has contributed to an increased aware-
ness of the palliative care needs of people with neurological disease, in particular consideration of  
the symptoms of advanced neurological disease, the role and effectiveness of palliative care for 
this patient group, the difficult ethical decisions that arise and the development of guidelines to 
provide support for the improvement of care.   
 
This first chapter will introduce the concept of palliative care and how this relates to people with 
neurological disease, and the development of this concept over the last 50 years.  There will also 
be discussion of the ethical and cultural aspects of care. 
 
1.1. Palliative care 
 
Palliative care is defined by the World Health Organisation as: “An approach that improves the 
quality of life of patients and their families facing problems associated with life-threatening ill-
ness, through the prevention and relief of suffering, early identification and impeccable 
assessment and treatment of pain and other problems, physical, psychosocial and spiritual”(WHO 
2002 ). 
 
Palliative care therefore aims to provide a holistic approach for patients and their families and in 
the UK, this may be within an inpatient hospice, at home, in a day hospice, care home or in hospi-
tal. This is a multidisciplinary approach including medical, nursing and other professionals, often 
together with volunteers. 
 
Although these principles underpin all palliative care there are differences in how the terminology 
is understood, both within the UK and in other countries.  “Hospice care” may be used inter-
changeably with palliative care but this is not always so. For instance, in Germany a palliative care 
unit within a hospital aims at intervention in crisis and the management of symptoms, whereas in-
patient hospice care is mainly at the end of life (Radbruch et al 2009).  There is a similar differenti-
ation in the USA, particularly as to have funding for hospice care the patient should be within the 




There has also been discussion of the levels of palliative care and the European Association for 
Palliative Care (EAPC) White Paper on palliative care suggested three levels of provision: 
• Palliative care approach, which should be part of all patient care, ensuring good commu-
nication with patient and family, shared decision making and goal setting and symptom 
management.  All services should provide this basic care. 
• General palliative care would be provided by primary care professionals and specialist 
services caring for patients with life threatening illness. Palliative care may not be the en-
tire focus of their role but they should have additional expertise, acquired from special 
education and training. 
• Specialist palliative care provided for patients with more complex issues, which may not 
be covered by other services. The team would have this as their main activity and have 
received specialist training and continuing education (Radbruch et al 2009).  
 
There is often confusion as to what level of care is provided, and by whom. This can lead to fur-
ther confusion in the development of services. Palliative care is important for the care of patients 
and families and may be as a palliative care approach, by all professionals, general palliative care, 
from neurology, rehabilitation and primary care services, and by specialist palliative care for more 
complex issues. At all times there will be a need for close collaboration between all the profes-
sionals involved. There is also a move to use a public health approach, with a more unified 
approach. This would include patients, families, professionals, communities, governments and so-
ciety, working together to improve care, particularly at the end of life, for all people with needs, 
regardless of diagnosis. (Abel and Kellehear 2016) 
 
1.2 Historical perspective of the provision of palliative care for people with 
neurological disease 
 
Although the traditional view has been that hospices care for people with cancer, palliative care 
has been provided for people with neurological disease by specialist palliative care / hospices for 
some time. In 1967 St Christopher’s Hospice was opened in Sydenham, London, by Cicely Saun-
ders as a new institution dedicated to the care of the dying, with the new dimensions of the 
facilitation of teaching and research. Although the emphasis was on the care of patients with can-
cer, patients with motor neurone disease (MND) and multiple sclerosis (MS) were admitted to St 
Christopher’s Hospice from soon after the start and Dame Cicely Saunders wrote of this to Dr 
Mary Toms in 1990 – “we have been caring for patients in the terminal stages of Motor Neurone 




publications on palliative care of people with MND was published in 1981 from the experience at 
St Christopher’s Hospice (Saunders et al 1981.) 
 
 
1.3 Palliative care provision for patients with neurological disease 
 
In the UK there are over 220 hospices caring annually for 200,000 people and 83% of this care is in 
the community – at home or care home (Hospice UK 2015). However, over 95% of people receiv-
ing hospice care have cancer. 88% of all cancer patients receive palliative care at some time 
during the progression of their disease (NCPC 2010), whereas only 1.2% of surveyed neurological 
patients had contact with a palliative care team (Neurological Alliance 2015).  There is greater in-
volvement with people with non-cancer diagnoses, including neurological disease, within 
specialist palliative care hospital teams and day hospices, where they contribute 25% of referrals. 
Compared to cancer fewer patients with neurological disease die at home or in a hospice – for 
neurological patients 5% of deaths are in a hospice and 18% at home, compared to 16% of cancer 
patient deaths in a hospice and 29% at home. Moreover, this had not increased substantially over 
the 13-year period up until 2015 (National Neurological Intelligence Network 2015). 
 
1.4 Evidence of need for neurological palliative care 
 
Within the UK the numbers of patients with progressive neurological disease are large – the  
estimates of prevalence in England are MND 3750, Huntington’s disease (HD) 6580, MS 84,000, 
Parkinson’s disease (PD) 106,680, multiple systems atrophy (MSA) 2520, progressive supranuclear 
palsy (PSP) 5880 and dementia 665,070 (Neurological Alliance 2014).  All these patients face dete-
rioration, although the timescale varies, with MND having average prognosis of 2 to 3 years, 
whereas PD patients have an average prognosis of 15 years.  
 
Many surveys of patients with progressive neurological disease have shown there is a high symp-
tom burden and poor quality of life. A survey of patients across Australia showed all patient 
groups rated their quality of life below average, had multiple symptoms, often were shown to 
have depression, and were often dissatisfied with the care they received (Kristjanson et al 2006). 
Although the response rate was only 25% and it is likely that the more able patients were more 
likely to respond, the figures do show that there are considerable issues, even in the earlier stages 
of disease progression. Other studies have shown high levels of symptom burden and palliative 
care need for PD (Ng 2018), MND (O’Brien et al 1992), MSA and PSP (Wiblin et al 2017), MS (Ed-




A cross-sectional study using the large Canadian Longitudinal Study on Aging of 50,000 people 
showed that neurological disease was associated with a higher somatic and psychiatric morbidity 
and increased use of medical services, including hospitalization (Wolfson et al 2018). This study 
was limited inasmuch as the conditions were self-reported by the participants and its cross-sec-
tional design prevents causal conclusions. In the Czech Republic a study using in-depth interviews 
with patients with MS and PD and their families showed many unmet needs, in particular relating 
to coping with the disease and securing professional help (Buzgova et al 2019). Although the 
study was small, with 11 patients, there was saturation of the themes that were identified.  
 
1.5 Care services for neurological patients 
The care of patients with progressive neurological disease varies greatly and involves neurology, 
rehabilitation and palliative care services.  The need for collaboration and involvement of pallia-
tive care has been emphasized for many years. The National Service Framework for Long-term 
Conditions (Department of Health 2005) recommended palliative care for people “in the ad-
vanced stages of long-term neurological conditions” and a Quality Requirement for 
comprehensive palliative care services was recommended, which may be provided “over an ex-
tended period of time” (Department of Health 2005).   
 
In 2010 the National End of Life Care Programme commissioned a report “End of life care in long 
term neurological conditions: a framework for implementation” (End of Life 2010).  I chaired this 
group and was influential in the writing of the report, which recommended palliative care should 
be considered at any stage of the disease progression and suggested the assessment for end of 
life care, including the consideration of triggers to identify this last 6 to 12 months of life, advance 
care planning, the careful management of symptoms and care for family and all carers (End of Life 
Care Programme 2010).  The triggers have been further investigated and have been shown to be 
valid for patients with neurological disease with an increasing number of triggers being seen as 
death approaches, and particularly in the last 6 months of life (Hussain et al 2014; Hussain et al 
2018).   
 
Although involvement with people with neurological disease has been suggested palliative care 
services have often been reluctant to provide support and care for these patients. Concerns have 
been expressed about the lack of experience in the care of neurological disease, the need for 




numbers of patients, the pressure on resources, the variable trajectory of disease progression and 
prognosis– from months to years, with varying caring needs over these periods of times - the diffi-
culty in identifying a dying phase, the complexity of assessment and care, and the difficulties in 
accessing community services and equipment (Wilson et al 2011; Gofton et al 2018).  More re-
cently, as part of the research project OPTCARE-NEURO (OPTCARE-NEURO 2019), investigating 
the effectiveness of a short-term palliative care intervention in neurological disease, a mapping 
exercise was undertaken of the neurology centres that were to be involved in the research. This 
showed a heterogeneity in the service provision and level of integration, but with greater integra-
tion for MND compared to other disease groups (van Vliet et al 2016).  An online survey of 
neurologists and palliative care professionals within these centres reported that 36% of neurology 
and 58% of palliative care professionals felt that collaboration was excellent or good and 45% of 
neurology professionals rated the current collaboration as poor or none (Hepgul et al 2018). 
 
Thus, the care provided for patients with neurological conditions varies across the country and 
there is evidence of poor collaboration between services caring for patients with neurological dis-
ease. 
 
1.6 Research in palliative care 
 
Research in palliative care is often complex as patients have progressive disease, multiple symp-
toms and comorbidities and may deteriorate and die within a short period of time. These issues 
are heightened in neurological care and these issues will be discussed further in Chapter 7.  The 
particular issues for the studies I have undertaken will be considered for each study. 
 
1.7 Ethical and cultural aspects 
 
The care of patients with progressive neurological disease will involve complex consideration and 
discussion of ethical issues: 
• Withdrawal and withholding of treatment. Increasingly interventions are undertaken that 
may affect survival and quality of life, such as the use of gastrostomy for maintaining nutrition 
and hydration, and ventilatory support when there is respiratory failure, particularly in MND.  
These interventions need to be considered very carefully as the benefits and risks may be 
finely balanced.  The withdrawal of non-invasive ventilation of MND patients at the end of 
life is an example of such an ethical situation. The research on these ethical aspects within 




• Cognitive change is common as neurological disease progresses and affects the ability of the 
person to make clear decisions, as capacity is lost. There are ethical considerations in enabling 
patients to make their wishes known earlier – advance care planning – as many people are 
resistant to looking ahead and considering their deterioration, even though discussion at 
these earlier stages may be the only opportunity they have to make their views known clearly. 
• Therapeutic or palliative sedation is the monitored use of medications intended to induce 
a state of decreased or absent awareness (unconsciousness) in order to relieve the burden 
of otherwise intractable suffering in a manner that is ethically acceptable to the patient, 
family and health-care providers (Cherny et al 2009).  This may be considered at the end 
of life, but may lead to ethical discussion and disagreement within the multidisciplinary 
team. There may be confusion when morphine and other medication for symptom 
management at the end of life are used, with possible sedative effects, and this has been 
an important issue in the discussion of end of life care.  
• Hastened death may be discussed by people with progressive neurological disease, 
including euthanasia and physician assisted suicide.  There is evidence that neurological 
disease is over represented within the people receiving a hastened death in the areas 
where this is permitted.  In the Netherlands in 2010 1.8% of all deaths were a result of 
euthanasia or physician-assisted suicide but 22% of MND patients received an assisted 
death, compared to 5% of cancer patients and 0.5% of people with heart failure (Maessen 
et al 2010). 
 
The papers presented in this thesis expose both ethical and cultural issues, particularly in the care 
of people at the end of life. The care of patients with neurological disease may vary greatly from 
country to country, depending on the culture and attitudes within each country.  This is seen par-
ticularly in the care of MND where, as has been shown above, in the Netherlands many with MND 
receive euthanasia or physician assisted suicide (Maessen et al 2014), whereas in Japan 15-20% 
have life extending treatment with a tracheostomy and invasive ventilation and may survive 10 to 
20 years, but often becoming “locked in” with no way of communication (Vienelloa and Concas 
2014). The aim should be to respond to each particular patient, within their own family and cul-
tural context, and within the norms and possibilities of treatment of the society (Lambert 2014). 













This Introduction has aimed to provide an overview of the context of palliative care for people 
with progressive neurological disease. In the following chapters I will discuss how my work has in-
fluenced neurological palliative care: 
• Establishing the need for palliative care for neurological patients – Chapter 2 Texts 1,2 
and 3 
• Establishing the involvement of palliative care with neurological disease, in particular 
MND – Chapter 3 text 4 
• Demonstrating the effectiveness of palliative care for people with neurological disease 
Chapter 4 Texts 1,2,5 and 6 
• Discussing the ethical and complex issues in neurological care Chapter 5 Texts 7,8,9 and 
10 
• Influencing care through the development of guidelines to facilitate the further develop-
ment of care and the education of professionals, patients, families and society. Chapter 6 
Texts 11 and 12. 
 
The next chapter will consider studies showing the needs of people with progressive neurological 




























This chapter aims to consider three papers which have investigated the palliative care needs of pa-
tients with neurological disease. Studies evidencing these needs were limited before my work.  
Two surveys for St Christopher’s Hospice had shown that symptoms and other psychosocial needs 
were common for people with MND.  The first study described the symptoms found in their retro-
spective survey of 100 patients at the hospice before 1980, with dyspnoea in 60%, dysphagia in 
41% and pain in over 40% (Saunders et al 1981).  A later survey, considering 124 deaths between 
1980 and 1990 described pain in 71%, dyspnoea in 58% and drooling in 47% (O’Brien et al 1992). 
These were both retrospective surveys from the notes kept at the hospice, which may not have 
recorded symptoms accurately and would have involved many different clinicians in the comple-
tion of these records. 
 
I have been closely involved with three studies looking at the needs of both MND patients and a 
mixed group of neurological diseases. 
 
2.2 Experience of the Wisdom Hospice – a Case review - Text 1 Oliver 1996 
 
2.2.1 Research study 
 
A retrospective review from the patient notes was undertaken at the Wisdom Hospice of 52 pa-
tients with MND who had died under our care between 1985 and 1995, the majority of whom I 
had seen from soon after diagnosis until death (Text 1 Oliver 1996).  At every recorded contact the 
symptoms and other issues were noted, medication was recorded in a specific chart for patients at 
home, and at every out-patient clinic appointment this was updated. The medication charts were 
available if the patient had been admitted to the hospice. Although from a single service, these 
patients were demographically similar to other studies on MND, with 38% female, average age of 
63 years for women and 68 years for men, and an average duration of the disease of 26 months.  
  
2.2.2 Findings   
 
The retrospective case note review, showed that symptoms were very common – for patients dy-
ing at home the common symptoms that were recorded at any time from first contact until death 




The symptoms and issues were recorded at all clinic appointments, admissions to the hospice and 
other contacts in the notes, but not using a specific tool.  These were similar symptoms to the ear-
lier St Christopher’s Hospice studies but the frequency of symptoms was higher.  This may have 
been seen as the patients were under my care for a long period of time, as referral was made soon 
after diagnosis and I was involved until death and as the records were primarily made by myself, 
with close colleagues on occasions, they would be more likely to be accurate and complete.  
 
The review also showed that patients were often able to remain, and die at home, with 48% of the 
group dying at home. Overall 82% of the care of all the patients was at home, and admission to the 
hospice was often for a short period only before death. No patients were admitted to hospital. The 
medication used was also described and this will be considered in Chapter 4. 
 
A larger proportion of the patients who were admitted to the hospice were found to be female, those 
living alone, unmarried or divorced and with bulbar symptoms, whereas those who died at home were 
more commonly male and supported by a partner, who was able to provide care at home.  
 
2.2.3 Strengths and limitations 
 
There are concerns that a case note review may not always provide accurate information and may be 
of a selected group (Hess 2004) but in this retrospective case review the medical notes can be assumed 
to be both accurate and available as I had been closely involved in the care of the patients, the 
assessment of symptoms and the prescription of medication. However, this may have introduced bias, 
as the assessment may have not been impartial. 
Although the series was a single cohort, with no control group, the accuracy of the records was good 
and selection bias was unlikely as all patients known to the hospice were included, and at that time 
most patients known to any neurological or rehabilitation service or to the MND Association were 




This paper has added to the evidence that patients with MND have many symptoms and despite these 
symptoms, patients were able to die at home. This has been important, as will be discussed again when 







2.3 Experience in Rochester and Munich Text 2 Neudert et al 2001 
 
2.3.1 Research Study 
 
Following the initial case note review described above a further review of the later stages of life of MND 
patients seen at the Wisdom Hospice between 1991 and 1999 was undertaken and reviewed in 
collaboration with a team in Munich, who reviewed their patients with MND who were on the database 
of the Motor Neuron Outpatient Clinic, who were cared for at home and died between 1995 and 1999 
(Text 2 - Neudert et al 2001).  This was a comparative two site study. There was some overlap with the 
previous group which had considered patients dying between 1985 and 1995, as patients who had died 
between 1991 and 1995 were included in both studies.  
 
The review at both centres was again retrospective using the clinical notes of 50 patients, using an 
identical procedure. In Munich the case note review of 121 patients was combined, where possible, 
with a telephone interview of the caregivers or nurses who had been present at the time of death. The 
two groups were similar in the patient characteristics – in Munich 59% male, mean age 63 years, 
duration of the disease 36 months, 31% bulbar onset; at the Wisdom Hospice 56% male, mean age 66 




The symptoms that were recorded in the last 24 hours of life were broadly similar: dyspnoea 20% in 
Munich, 30% Wisdom, restlessness 8% and 6%, choking on saliva 7% and 0%, coughing 4% and 20% 
and pain 2% and 1%.  The study showed that the assessment of death, from the comments of carers or 
from the records in the notes, was that it had been peaceful for vast majority of patients– 88% in 
Germany and 98% at the Wisdom Hospice. Six patients in Munich had died after a resuscitation 
attempt, which had highlighted the need for earlier discussion as all six relatives considered, in 
retrospect, that this attempt had been a mistake.  The findings concerning the medications used to 
manage symptoms will be considered in Chapter 4. 
 
2.3.3 Strengths and limitations 
 
This paper is again following a retrospective review of case notes, although in the Munich arm of 
the study this was combined with telephone conversations with the carers, either family or 
professional.  There could be selection bias in the telephone results as only two thirds of the families 




although as the comments could be compared to the case note records this was unlikely.  The 
assessment of the death as peaceful could have been influenced by the bias of the researchers. 
Moreover, it was less likely that distress would be recorded in the notes and families and carers may 
have been less willing to talk of distress in the interview. The two groups were very similar, with no 
significant differences found in the sex ratio, age, mean duration of the disease, sites on onset and 




This paper has been widely quoted in other literature.  The results have shown that dying with MND is 
usually peaceful, when the patient and family have received palliative care and has been very important 
in refuting the assertions that a death from MND is distressing  - for instance in the section about Diane 
Pretty on the Dying in Dignity website where there is discussion of  “the fear of dying by choking or 
suffocation” (https://www.dignityindying.org.uk/story/diane-pretty/ Accessed June 2020). This will 
be discussed further in Section 4.3.4. 
 
2.4 Qualitative study in Turin Text 3 Veronese et al 2015 
 
2.4.1 Research study 
 
To inform the development of a Randomised Controlled Trial of palliative care for neurological pa-
tients– see Chapter 4– a qualitative exploration of the needs of patients and families was 
undertaken.  This was part of the study by Simone Veronese for his PhD studies.  I was his supervi-
sor for this study and closely involved in the design of the study, the analysis of the results and the 
later writing of the paper (Text 3 Veronese et al 2015). 
 
Simone Veronese interviewed 22 patients in Turin with MND, MS, PD and MSA, who were consid-
ered to be in the later stages of disease progression and might die in the next 6 months, were able 
to communicate themselves or with a communication aid, could give informed consent, and were 
resident in Turin. Their caregivers (n=21) were included if the patient consented, and they were 
able to do so and agreed.   Focus groups were also held with health and social care professionals 









• Physical - including movement issues (100%), swallowing and speech (95%), pain (82%), 
breathing issues (82%), bowel problems (73%) and sleep issues (64%) 
• Psychological – feelings of being abandoned (96% of patients and 64% of carers), mood 
instability, anxiety and depression (mentioned 25 times), difficulties in coping with contin-
ual loss (19 mentions) and feeling overwhelmed (17 mentions) 
• Social – of isolation (13 mentions), family problems (13), transport issues (14), issues with 
a paid carer (16) and difficulty obtaining benefits (12) 
• Spiritual – loss of hope (5 mentions) and meaning of life as they approach death (11), 
rage, loss of control (7) 
 
Comments from both patients and carers supported these findings, and provided a depth of un-
derstanding the issues and the impact on all involved. Many unmet needs were identified. 
 
The professional carers were aware of the high burden of symptoms and issues and some  
recognised that they lacked expertise in managing some of these issues.  They did accept that 
there was a need for psychological, social and spiritual support to help the patients and families, 
and to improve their quality of life.  They also felt that they were unable to care for these patients 
when they were no longer able to attend a clinic at the hospital and they could see the need for 
palliative care (Text 3 Veronese et al 2015). 
 
2.4.3 Strengths and limitations 
 
There are limitations within this study. This was a small sample and the group was neurologically 
heterogeneous. The heterogeneity may have reduced the sensitivity of the study in elucidating the 
issues for specific diseases, although the careful interviewing of each participant would have allowed 
the issues to be discussed for each individual. However, the involvement of the different diseases did 
provide clear evidence that there was a commonalty of the issues faced by patients with progressive 
neurological disease.  
 
The interviews of patients, often with family members present, provided a rich source of data 
about the needs and concerns of the patients.  Simone Veronese undertook these interviews, 
sometimes using communication aids as the patients could not communicate verbally. He had not 
been involved in the care of these patients before, and this limited the possible effect of the pa-
tient feeling pressurised to take part in the interview. As he was involved in the provision of care 




care provided.  Patients asked for their family to be present and they were often able to help in 
clarifying what the patient wished to say, if communication was difficult. In this way bias was re-
duced, although there were concerns that patients and families may have felt pressurised to take 
part, as they wanted the possibility of extra care and support, and may have over or under empha-
sised their problems. The family members may also have affected the responses of the 
participants, as the patient may have not wanted to distress the family in their response. 
 
The focus groups of professionals were held at their hospitals and they were encouraged to talk 
about the needs of patients with progressive disease, using a prepared schedule.  There are 
limitations that within the group there may be dominance by certain participants and others may feel  
inhibited to speak. This was minimised by careful explanation of the role of the focus group and  
facilitation of the group itself, encouraging all to be involved. 
 
The strength of this study was in the single interviewer using a similar approach for all participants and 
leading all the focus groups.  This allowed for consistency in the interviews and focus groups and an 
iterative approach could be taken, with the earlier interviews and groups informing the later 
discussions. This, however, may also be a limitation as there is the possibility of bias as the same person 
was providing and assessing the intervention. More severely affected patients with communication 
issues were not excluded, as the interview was able to continue with a communication aid. Patients 
were affected by a heterogeneous group of neurological conditions, which allowed a greater 




These results showed that there were many unmet needs experienced by this patient group, and 
their carers.  This can be seen in the number of issues raised by patients and their caregivers and 
the qualitative approach allowed a richer depth of understanding into these issues, with the use of 
comments from patients in the paper. Although these were often recognised by the professionals 
involved in their care, they often felt unable to offer support, particularly as the patients become 
more disabled and unable to attend for out-patient clinics.  The support for patients at home was 
limited, depending on the interest and expertise of their general practitioner, who provides day to 
day care.  The results again identify the needs of patients, and in this study from a wider group of 






Within the literature on MND the two papers (Text 1 Oliver 1996; Text 2 Neudert et al 2001) have been 
influential in showing that dying with MND can be peaceful, with good palliative care and symptom 
management, and have been used in the discussions about dying with MND, particularly in the 
arguments about assisted dying- this will be further discussed in Section 4.3.4.  The paper from Turin 
(Text 3 Veronese et al 2015) is one of the only papers looking at a group of neurological disease in the 




These papers have provided new evidence about the needs of people with progressive neurological 
disease and they have been reinforced by later studies (Ng 2018; Wiblin et al 2017); Edmonds et al 
2010; van der Steen et al 2014). 
  
Building on these studies which demonstrated the needs that patients have for palliative care the next 
chapter will consider the evidence that specialist palliative care involvement makes a difference for 



































Other than two studies from St Christopher’s Hospice (Saunders et al 1981; O’Brien et al 1992) 
there was little information when I commenced my work about the involvement of specialist palli-
ative care services in the care of people with progressive neurological disease. 
I collaborated on a paper in 2000 looking at the involvement of hospices in the care of people with 
MND.  
 
3.2 Survey of hospices Text 4 Oliver and Webb 2000 
 
3.2.1 Research study 
 
In 2000 Dr Sandi Webb and I undertook a questionnaire survey of specialist palliative care services 
in the UK to ascertain their involvement in the care of people with MND. 229 hospices were con-




170 hospices responded (77%). Their involvement with people with MND varied greatly - only 17% 
were involved from soon after diagnosis and 48% only saw patients in the terminal stages of the 
disease.  Care was provided primarily in the inpatient hospice and only 61% provided care at 
home. The commonest areas of care provided were symptom management (92%), respite care 
(91%) and care at the end of life (84%). 
 
There did seem to be involvement of the wider multidisciplinary team within many of the hos-
pices, although speech and language therapy was only involved in less than 25% of the hospices 
and dietitian in only 21% of the home care services. The study also showed that collaboration with 
other local services was limited, with only 14% collaborating with disability services, 23% with 
neurology and 36% with the MND Association.   
 
3.2.3 Strengths and limitations 
 
This study does have limitations. The use of the postal questionnaire allowed information to be 




Directory. The data was then anonymised and analysed together. Although the response rate was 77% 
there could be bias, as those who responded may have been more involved in MND care than the non-
responders.  With the use of a questionnaire there is the risk that there could be misunderstanding or 
misinterpretation of the questions, leading to inappropriate and incomplete responses. This was 
minimised by a careful assessment of the questions and a pilot questionnaire being used at the authors’ 




This paper was published in Palliative Medicine, the official journal of the EAPC, and has helped to 
raise awareness of the role of specialist palliative care for MND patients and shown the role of 
earlier involvement and close collaboration across the multidisciplinary team and with other 
teams.  The results were presented as a poster at the MND/ALS symposium and have been used in 




There is very little evidence of the involvement of palliative care in the care of people with neuro-
logical disease.  There has been increasing awareness for the need for collaboration between 
neurology and palliative care (End of Life Care programme 2010; Turner-Stokes et al 2007). A study 
in 2013 considered the place of death, obtained from the Mortality Statistics in England from 1993 
to 2010 and found the proportion of deaths in hospices was 0.6% for PD, 2.5% for MS and 11.2% 
for MND (Sleeman et al 2013). Thus, MND would still appear to be the most common neurological 
disease receiving palliative care. 
 
In New Zealand a survey of hospices showed that of the 35 services that replied – 85% of the 41 
contacted - all cared for MND, although some did state that this would only be in the terminal 
stages.  There were concerns about the resources needed for this care, the complexity of the mul-
tidisciplinary approach, the knowledge needed and the uncertainty of prognosis (McKenna and 
MacLeod 2005). The paper shared examples of good practice where there was shared care be-
tween the rehabilitation team and palliative care. Text 4 Oliver and Webb 2000 was quoted within 






The level of collaboration between palliative care and neurology has been studied as part of the 
OPTCARE-NEURO research project to investigate short term palliative care input for neurological 
disease patients (0PTCARE NEURO 2019).  This showed a wide variation in collaboration but with a 
more integrated approach to MND, a less integrated approach for PD and related diseases and the 
least collaboration for MS (van Vliet et al 2016).  In Germany an online survey of neurological con-
sultants found that they felt 10% of patients with progressive neurological disease would benefit 
from hospice care (Golla et al 2016).  Moreover, the level of collaboration varied from 50% to 78% 
and only 12% had received any training in palliative care. 
 
Following the involvement of palliative care, the next chapter will consider the effectiveness of 








































The evidence base for the effectiveness of palliative care is limited for all disease groups. Thus, 
there is a need to develop the evidence for the use of palliative care for people with progressive 
neurological disease so that the care provided can improve, and quality of life for patient and fam-
ily maintained at as good a level as possible.    
 
The papers described here consider the assessment of effectiveness of palliative care for neuro-
logical patients, in particular the management of symptoms, the maintenance of quality of life and 
the care at the end of life, in particular the aim for death at home and peaceful death.  
 
4.2. Experience from the Wisdom Hospice Case Review – Text 1 Oliver 1992 
 
4.2.1 Research Study 
 
This study was a retrospective review of the notes of patients dying at the Wisdom Hospice and 




As discussed in 2.2.2 the study showed that despite many symptoms patients often died at home 
(48%). The study also considered the use of opioid medication in the management of symptoms 
and of the patients dying in the hospice, where accurate records of medication were available, 
85% received oral morphine, 70% injection of diamorphine and 59% a continuous subcutaneous 
infusion of diamorphine via a syringe driver.  Moreover, the doses of morphine were not large – 
the mean dose at home was 90mg oral morphine equivalent / 24 hours and the mean duration of 
use was 240 days. This shows that morphine had often been administered over a period of several 
weeks and months. 
 
 
4.2.3 Strengths and limitations 
 
The limitations of a retrospective review have been discussed in 2.1.3. The lack of a control or 
comparison group limits the study but the findings do suggest that care can be provided and med-







This study has been cited widely and has added to the evidence for the involvement of palliative 
care in the care of people with MND and opioid medication can be used safely, with limited evi-
dence of it effectiveness in symptom management, for people with MND.  
 
4.3 Experience in UK and Germany – Text 2 Neudert et al 2001 
4.3.1 Research study 
 
This was a retrospective case review of people dying of MND at the Wisdom Hospice (50 patients) 




The study showed that people with MND were able to die peacefully – as recorded in the notes or 
from discussion with family or carer after death – with 88% of patients in Germany reported as dy-
ing peacefully and 98% under the care of the Wisdom Hospice.  Moreover, 52% of the patients in 
the UK and 55% of the patients in Germany died at home. 
 
The study also looked at the use of opioids and showed that many people received morphine – 
27% in Germany and 82% in the UK.  The difference may reflect that hospice care is significantly 
less available in Germany, with only 6.4 hospice beds/million population compared to 54 
beds/million in the UK.  The majority of patients in Munich were cared for at home and attended 
on a regular basis for out-patient clinics, but were less likely to receive ongoing care at home.  The 
primary care services may be less aware of the use of morphine for this patient group, whereas in 
the UK there was regular contact from specialist nurses at home, working in collaboration and 
supporting primary care. The doses were not high with a mean dose of 90mg oral morphine equiv-
alent/24 hours in Germany and 115mg oral morphine equivalent/24 hours in the UK. The duration 
of use was only available in Germany, with a mean duration of use of 6 days, with a range from 








4.3.3 Strengths and limitations 
 
The limitations of a retrospective review have been discussed in 2.2.3. Although the results show 
that death was peaceful in the group studied, this was not compared to a control group.  Further 




This paper has provided data showing that people with MND are able to die at home, may receive 
morphine in the later stages of life at a moderate dose which was beneficial and death was felt to 
be peaceful in over 85% of patients - comparable to or higher than for other patient groups (Cagle 
et al 2015).  This paper has been widely cited and has been used to show that people may die 
peacefully with MND, if they have received palliative care, including symptom management and 
support of the patient and carers. This has been used to repudiate the claims of some pro-eutha-
nasia organisations, when MND is described in very negative terms and death from MND is 
described as distressing and to be feared, as discussed in 2.3.3.  
 
The MND Association has a booklet “A professionals guide to end of life care in MND”, for which I 
provided advice, has a section stating  “Death in the majority of cases is very peaceful, following 
lengthening periods of sleepiness, gradually resulting in a coma” supported by a reference to Text 
2 Neudert et al 2001 (MND Association 2019). A review article in Lancet Neurology entitled “End 
of life management in patients with amyotrophic lateral sclerosis” discusses patients fears of chok-
ing to death and uses the results from Text 4 to state “patients with ALS die peacefully” (Connolly 
et al 2015). 
 
4.4 Opioid use in MND – Text 5 Oliver 1998 
 
4.4.1 Research study 
 
A retrospective case note review of 32 patients dying at the Wisdom Hospice between 1985 and 
1996 was undertaken looking at the use of opioid medication. As these patients had died at the 
hospice the full medication chart and medical and nursing notes allowed the indication, dose, du-










Of the 32 patients 75% received oral morphine, 94% received parenteral opioids and 72% received 
both oral and parenteral opioids.  The mean dose of oral morphine was 96mg/ 24 hours, the me-
dian dose 60 mg/24hours and the range was from 15 to 720mg/24hours.  The mean duration of 
use was 95 days, with a range of 2 to 970 days. This was lower than the group in Text 1 Oliver 
1992, although in the earlier study both patients dying in the hospice and at home were included, 
and this may reflect that patients who are able to remain at home may take morphine for a longer 
duration of time (Text 1 - Oliver 1992). The main indications for morphine were pain 50%, dysp-
noea and /or cough 34%, insomnia 6% and in the final stages of life only for 10%.  The 
effectiveness was assessed from the notes, by myself, as “good” or “fair” for all patients and dif-
fered according to indication – the assessment was good for 69% for pain relief, 54% for dyspnoea 
/ cough and 100% for terminal distress.  
 
4.4.3 Strengths and limitations 
 
The limitations of a retrospective case note review have been discussed in 2.2.3. As the patients 
died at the hospice the information on the dose and duration of use was accurate but the assess-
ment of indication or effectiveness was subjective and obtained from reading the notes.  These 
could be subject to bias, as I was both prescriber and assessor. I had aimed to be objective as pos-




This paper, together with Text 2 and O’Brien et al 1992 and Saunders et al 1981, are the only refer-
ences quoted in the Cochrane Systematic Review “Drug therapy for pain in amyotrophic lateral 
sclerosis or motor neuron disease” in the section on opioids (Brettschneider et al 2013).   
 
A review of pain in MND (Stephens et al 2016) reviews their experience and three papers on pain 
in MND. In Italy opioids were given to 14% of 91 assessed patients  (Chio et al 2012); in the UK 
29% of patients attending a specialist MND clinic with pain received opioids (Wallace et al 2014); 
13% of MND patients attending a specialised outpatient clinic in Germany received opioids 
(Hanisch et al 2015); and in the US series 22% received opioids (Stephens et al 2016).These studies 
were all a survey of a group of MND patients at a specific time point, whereas the Wisdom Hos-
pice series includes the use of opioids by patients over the course of their care, often from soon 





Thus, this paper has shown that opioids may be given over extended periods of time and has pro-
vided evidence for the safe use of opioids in MND and has contributed to the Cochrane Review. 
 
 
4.5 Randomised controlled trial – Text 6 Veronese et al 2017 
 
4.5.1 Research Study 
 
This study was a randomised controlled trial investigating the effectiveness of a specialist palliative 
care approach over 4 months.  The study was part of the PhD project of Simone Veronese from 
Turin, Italy.  I was his PhD supervisor and was closely involved in the design of the study, the analy-
sis of the results and the writing of the paper – Text 6 – Veronese et al 2015. 
  
A phase 2 pilot randomised controlled trial was undertaken. The Phase 2 study is defined in the 
MRC Framework as an “exploratory trial”, which would “describe the constant and variable com-
ponents of a replicable intervention and a feasible protocol for comparing the intervention with 
an appropriate alternative” (Campbell et al 2000). The intervention was the involvement of a mul-
tidisciplinary specialist palliative care service in Turin (FARO) using a waiting list methodology, with 
a fast track (FT) versus standard track (ST) approach.  50 patients with advanced neurological dis-
ease, defined from the specific criteria for MS, MND and PD and associated diseases, were 
randomised either to FT, with the involvement of the team from the time of recruitment, or to the 
ST, where the team was only involved after 16 weeks. 
   
The Primary outcomes were the effects of 16 weeks provision of specialist palliative care on indi-
vidual quality of life – measured using the SEIQol-DW – and the caregivers’ burden of care using 
the Caregiver Burden Inventory.  Physical symptoms, psychological issues, social issues and spir-
itual issues were assessed using Numerical Rating Scales, anxiety and depression using Hospital 





Of the 50 patients enrolled 60% were male and the mean age was 61 years. The diagnosis was 




were no statistical differences in the groups.  Only 2 patients dropped out, in the FT group, for per-
sonal reasons. There were two deaths in both the FT and ST groups. 
 
Statistically and clinically significant changes were seen in the FT group for quality of life, and phys-
ical symptoms – pain control, breathlessness, sleep disorder and bowel symptoms – compared to 
the ST group. There were no differences in caregiver burden. There were positive trends for im-
provement in other physical symptoms, service satisfaction and help in finding a meaning in the 
experience of the disease and social isolation. Psychological issues appeared to have a trend to 
worsening of symptoms, which may have been partly due to the increased discussion of these is-
sues and confronting the concepts of death and dying. 
 
4.5.3 Strengths and limitations 
 
This approach was chosen as it is considered to be the “gold standard” of evidence on the effectiveness 
of an intervention, compared to a placebo or an alternative intervention. The randomisation into the 
intervention and control group at baseline ensures an equivalence of the groups being compared, and 
this was tested and confirmed statistically in the study (Text 6 Veronese et al 2017). However, there is 
a risk of a selection bias in the recruitment of participants for inclusion in the study (Higginson et al 
2013).  The recruitment was from a specialised hospital clinic in Turin by professionals, including 
neurologists, rehabilitation clinics and respiratory services. There could have been selection bias in 
recruitment, as these professionals may have tended to include patients who were less disabled, and 
patients who attended other general neurological clinics or were too ill to attend the specialised clinic 
may have been excluded. The referred patients were shown to have severe disease at the baseline and 
there were no statistical differences between the groups – the  Expanded Disability Status Scale (EDSS) 
scores of patients with MS were a mean of 8.5, where over 8 presents patients restricted to bed or 
chair, ALS Functional Rating Scale - Respiratory (ALSFRS-R) scores for MND patients showed a mean of 
10.2, out of a full score of 48 showing severe disease and disability and a Hoehn and Yahr score for PD 
patients of 4.2 which is described as “severely debilitating” (Veronese et al 2017). 
 
The MRC Framework for a Phase II “Exploratory Trial” was used to investigate this complex intervention, 
which involves multiple interacting components with variability in content, context and mode of 
delivery, and often unpredictability of the overall effect (Hepgul et al 2018). A Phase II study has been 
suggested, when the intervention is complex and is still being developed and the trial will help to assess 
recruitment, drop out, mortality and feasibility (Campbell et al 2000).  This approach had been further 




Researching End of Life Care (MORECare) collaboration (Higginson et al 2013). There had been a similar 
Phase II trial for patients with MS (Higginson et al 2008). 
 
As the trial involved people with advanced progressive neurological disease, it would be very difficult 
to provide a blinded intervention – with a “Placebo intervention” from a multidisciplinary team. A 
waiting list RCT was undertaken, with the participants randomised to the intervention of palliative care 
immediately or to a control group who only received the intervention after 16 weeks (Higginson et al 
2006).  In this way all patients would receive the intervention, and although all patients would have 
progressive disease, the likely prognosis was usually in terms of months to years and the delay would 
not adversely disadvantage patients who were randomised to the standard best practice arm - the 
disadvantage was time-limited, as although they would not receive the intervention immediately they 
would all receive the intervention after 16 weeks. As this was part of a limited PhD project it was not 
possible to have blinded assessment, as the investigator undertook all assessments, which could lead 
to bias.  
 
There were limitations in this approach, as due to the feasibility of undertaking the study the numbers 
of patients were limited to 50 overall and there was a mix of patients, with different progressive 
neurological diseases.  
 
4.5.4 Contribution  
 
There are few studies looking at the effectiveness of palliative care interventions and these have 
usually been in the care of cancer.  This is the first study looking at three advanced neurological 
diseases and using a full multidisciplinary specialist team approach.  This may partly explain the 
positive results whereas the other studies have limited results – for instance a short-term inter-
vention for people with MS. 
 
Studies in London for patients with MS showed that there was an improvement in symptoms in 
the group receiving palliative care, whereas there was deterioration in the control group (Ed-
monds et al 2010). Moreover, there was an improvement of caregiver burden (Edmonds et al 
2010) and this care was shown to be cost effective (Higginson et al 2009).  A more recent study in 
Italy showed that the short-term involvement of specialist nurses, who had received extra training 
in palliative care and support, did lead to a reduced symptom burden but had no effect on quality 
of life or other outcomes (Solari et al 2017).  This study – Text 6 Veronese et al 2015 – did show 




and specialist palliative care team with regular visits throughout the study period, whereas the 
other studies involved short term, limited input and did not have a full multidisciplinary specialist 
palliative care approach. 
 
The evidence for the effectiveness of palliative care for cancer patients, has been limited. A trial in 
2010 showed that early palliative care for patients with non-small cell lung cancer improved not 
only quality of life and mood, but led to a longer survival (Temel et al 2010).  More recently, a 
study with newly diagnosed patients with lung and gastro-intestinal cancers involved 350 people, 
with a monthly consultation with palliative care, showed that there was an improvement of qual-
ity of life after 24 weeks and the lung cancer patients showed an improvement in quality of life 
and depression at 12 and 24 weeks, whereas the control group deteriorated (Temel et al 2017). A 
recent trial in Denmark showed no evidence for the effectiveness of palliative care for cancer pa-
tients, apart from in the management of nausea and vomiting (Groenvold et al 2017).   
 
Thus, this study has provided clear evidence for the effectiveness of palliative care on both quality 
of life and symptom burden in neurological disease and may reflect the need for a wider multidis-
ciplinary team approach for this patient group, to assess and manage all aspects of care. This may 
be supported by studies that have shown that a multidisciplinary team approach for people with 
MND, with a specific MND team, with palliative care involvement and collaboration, showed an 
improvement in length of life (Aridegbe et al 2013; Rooney et al 2015). There may be aspects of 
multidisciplinary care that are important and studies are needed to elucidate the most important 
aspects of this approach to care. 
 
The study has been widely cited, including within the EAN/EAPC Consensus paper (Text11- Oliver 
et al 2016) and the other studies on neurological palliative care – in OPTCARE-NEURO (Hepgul et al 




There is limited evidence for the effectiveness of palliative care. A Cochrane Library Systematic Re-
view considered 23 studies, with 37,561 participants and 4042 family caregivers, to evaluate the 
effect of home palliative care services for patients with advanced illness (Gomes et al 2016). The 
meta-analysis showed that there was evidence that patients were more likely to die at home and 
evidence of the reduction in symptom burden in four studies, showing small, but statistically sig-




of cost effectiveness. A similar Cochrane Review on palliative care interventions for people with 
MS showed no evidence for an effect on quality of life, serious adverse events or hospital admis-
sion (Latorraca et al 2019).  Other studies have shown that palliative care is helpful in MS (Solari et 
al 2017) and as part of a wider multidisciplinary care in MND (Aridegbe et al 2013; Rooney et al 
2015). 
 
These studies have all provided increasing evidence for the effectiveness of palliative care for peo-
ple with neurological disease and added to the literature on this area.  
 
The next chapter will consider the complexity of palliative care for neurological disease, when 








































Within the care of people with neurological disease there has been the increasing use of interven-
tion and new treatments. These often aim to improve quality of life, but there may be an 
extension of life as well. However, ethical dilemmas may be raised as a result of the discussion, 
and commencement, of these interventions, for although there may be an initial improvement in 
the patient’s condition and wellbeing the disease will continue to progress and they face increas-
ing issues, such as restricted mobility, deterioration in communication, swallowing and breathing 
and cognition. These issues have been considered in the papers presented below. 
 




This paper was developed after a discussion between the authors when it was apparent that there 
were serious issues facing all involved in the care of people with ALS/MND as more was known 
about the disease and new interventions were developed.  It was agreed to write this review pa-




A discussion paper was drafted looking at the difficult decisions that were faced by professionals, 
and patients and families, including the telling of the diagnosis, the use of gastrostomy, the use of 
assisted ventilation, end of life planning and requests for assisted dying. This was not a systematic 
literature review but was a review of the issues with supporting evidence, where possible, and a 
discussion of the issues. 
 
5.2.3 Review findings 
The paper aimed to encourage the readers to consider the way difficult decisions were ap-
proached, in particular the communication about the diagnosis of ALS/MND and the possible 





In the discussion of these areas of care the importance of careful and considered communication 
was stressed, as patients may have their own particular concerns of interventions – such as feel-
ings that death may be close if interventions are necessary or loss of control or feeling that they 
are “giving in”.  The need to explain the benefits and risks of procedures was stressed, together 
with earlier discussion so that time can be taken over decision making, rather than in an emer-
gency situation.  
 
For patients and families to make informed decision about the end of life there is a need for ear-
lier discussion and consideration of place of care and death, the use of interventions, such as 
cardiopulmonary resuscitation, and advance care planning.  These issues may also come to the 
form in requests for a hastened death, euthanasia or physician assisted suicide (PAS), and the 
need to explore the request was highlighted. 
 
5.2.4 Strengths and Limitations 
 
This was a review paper, using the literature, but was not a systematic review. The views were 
from the discussions between the authors and are subject to bias. However, the paper was devel-
oped from the knowledge and experience of two experts, with different experiences – neurologist 




This paper has been widely quoted and cited 59 times and has been important in the developing dis-
cussion on the management of difficult issues in MND – particularly the communication and ethical 
issues. In a recent systematic review on NIV the paper was clearly quoted: “Oliver and Turner high-
lighted that the use or non-use of NIV was one of the many decisions to be faced by an individual ALS 
patient on their journey of care” (Baxter et al 2019). The paper has also been quoted in a study con-
sidering the decision making for the use of tracheostomy (Ceriana et al 2017). 
 
Within the discussion of the use of gastrostomy the ethical and decision-making aspects are usually 
stressed. An analysis of a large cohort of people with MND quoted the paper in their assessment and 
discussion of the intervention (Bond et al 2019). A review article on the ethical aspects of decision 
making in the management of MND uses the paper in their discussion of attempts to have earlier dis-




deterioration (Eisen and Krieger 2013).  Foley and Hynes (2018) have also quoted the paper in their 
review of the issues in decision making in MND. 
 
Within the discussion on end of life care the paper has been quoted within a review in Lancet Neurol-
ogy, in particular stressing that the discussion of end of life issues may not be easy and are often not 
straightforward (Connolly et al 2015). Although there is increased awareness of the need to discuss 
potential issues earlier in the disease progression, before communication and cognition may be 
compromised there is still reluctance to do so (Rietjens et al 2017). Advance care planning is in-
creasing - so the person discusses the care they would wish in the future, if they are unable to 
make the decisions themselves and this is recorded or a proxy is appointed to make the decision 
on their behalf (Rietjens et al 2017).  
 
There is increasing discussion internationally about hastened death and euthanasia is now availa-
ble in several countries – Netherlands, Belgium, Canada, Luxembourg, Colombia- and PAS is 
available in many states in the USA and Victoria in Australia and assisted suicide is available in 
Switzerland. The issues of these discussions have been discussed within this paper. 
 
Thus, this paper has been able to stimulate further discussion on these difficult issues and has been 
widely read. 
 
5.3 Issues surrounding withdrawal of non-invasive ventilation – Text 8 Faull et 
al 2014 
 
5.3.1 Research Study 
 
Palliative medicine professionals have been involved in the withdrawal of NIV in MND. NIV is an 
intervention that may be used if the patient develops increasing respiratory muscle weakness 
causing respiratory failure.  Initially NIV may be used only at night, as symptoms are more pro-
nounced on lying down, but as the disease progresses NIV may be used more often, even to 24-
hour use.  At the same time the disease will progress with increasing weakness and other issues. 
Some people receiving NIV may then ask for its withdrawal, but this may lead to death within a 
short time and cause distress, unless medication is given to prevent this. This request is not very 





An online questionnaire was sent to all 993 members of the Association for Palliative Medicine of 
Great Britain and Ireland (APM), asking them for their experiences of the withdrawal of NIV, and 
how they felt challenged practically, emotionally and ethically on a scale of 0 to 10, with 10 being 






134 professionals, including 130 doctors, responded to the questionnaire. It is difficult to calculate 
a response rate as it is not known how many doctors would have been directly involved in the 
withdrawal of NIV in a patient with MND. However, 76 of the respondents had been involved and 
the responses were often profound and showed that these individuals had found the issues very 
difficult.  The challenges they perceived were often great. Of those doctors with direct experience 
of NIV withdrawal the ratings were at a score of 7 or greater for 42% of the respondents for practi-
cal challenge, 33% for ethical challenge and 37% for emotional challenge.  
 
In free text they discussed the time that was taken in planning the procedure, with multiple dis-
cussions across the MDT and coping with conflicts in the discussion with patients, families and 
other MDT members. Although they realised that the withdrawal of a treatment at the patient’s 
request was ethically sound, it felt as if they were causing the patient’s death and thus it felt dif-
ferent to the withdrawal of other treatment, particularly when death followed withdrawal within a 
short time. The emotional burden was great and 20% of respondents scored this challenge at 9 or 
10 and the main areas were felt to be management of the emotions of all involved in the discus-
sion and process, the support of others, resolving conflict and the issues for themselves in coping 
with the withdrawal process and the ensuing death. 
 
5.3.3 Strengths and limitations 
 
There are limitations of an on-line questionnaire as the respondents may be more likely to have 
strong views than those who did not respond.  The response rate was difficult to estimate as the 
number of people who had been involved in the withdrawal of treatment is unknown. However, the 
response rate from within the APM was probably less than 15% of the whole membership, but this is 
found widely in on-line surveys (Atkin et al 2017; Smallwood et al 2017). It is not possible to assess 
how valid these results would be in a larger group but other on-line questionnaires have been found 
to have good validity and reliability (Plaete et al 2016).  However, this initial questionnaire aimed to 




may have allowed issues to be more openly discussed by the respondents than in focus groups or in-
terviews. Although this may have biased the result, as people with more definite views may have 
responded, the views expressed were very clear and showed that there were many unresolved issues 




This paper was an initial scoping study to ascertain if there were issues for palliative medicine doctors 
when they were confronted with the withdrawal of NIV in MND.  The results did clearly show that 
were many issues, particularly in the support and conflicts within the MDT. This has led onto further 
studies – Text 9 Phelps et al 2015 – and the development of the national guidance document “With-
drawal of ventilation at the request of a patient with motor neurone disease: guidance for 
professionals” (APM 2015). This document has provided clear guidance on the discussions, proce-
dure, medication that may be used and the ethical issues.  It has been endorsed by the General 
Medical Council and the Coroners’ Society of England and published by the APM and is available on 
their website and also on the MND Association website.  Further discussion on the document is pre-
sented as Text 10 Faull and Oliver 2016. 
 
 
5.4 Ethical and legal issues of withdrawal of ventilation – Text 9 Phelps et al 
2015 
 
5.4.1 Research study 
 
This study followed from the on-line study in Text 8. A retrospective qualitative interview approach 
was taken, interviewing doctors who had withdrawn assisted ventilation from a person with MND in 
the past 5 years.  The doctors were contacted from the last study – if they had given their contact de-
tails – and doctors were also approached in the APM Neurological Special Interest Forum and from 
MND care Centres and specialist respiratory teams.  24 doctors were interviewed. The interviews 
were analysed thematically and coded.  I was involved in the design of the study, helping in recruit-
ment, interpreting the findings and the themes that were developed and in writing the paper, in 




Five main themes were found: ethical and legal aspects, all participants agreed that patients had a 




often lengthy, discussions; discussions with the family were important and could be complex; discus-
sions with colleagues were often complex and some colleagues opposed withdrawal of NIV and 
further lengthy discussion was needed and the support of peers was felt to be important; legal advice 
was experienced as very variable and, on occasions, inaccurate, increasing the stress on the doctors; 
there were ethical complexities as the doctors talked of the difficulty of removing the NIV, which led 
to death within a short time, and that this felt as if they were causing the death and this was even 
more difficult as the patient was usually conscious and may have planned the time of withdrawal. 
 
5.4.3 Strengths and limitations 
 
The use of a qualitative approach was necessary for this study as the aim was to look in detail at the 
experiences, perceptions and attitudes of the participants (Atieno 2009).  The use of interviews allowed 
the lived experience of the participants to be discussed and then analysed carefully, looking for 
common themes. The data was able to lead to further exploration of the issues, as the researcher was 
able to adjust the interviews according to the particular participant, and using the experience from the 
previous interviews to help in the discussion.  
There are limitations to the qualitative approach as the data found can depend on the experience of 
the interviewer in gaining trust and openness of the participants (Atieno 2000). There was purposive 
sampling, using the doctors who had been involved in the earlier study, who had offered to provide 
further information, and then contacting others through MND centres and clinics, and by a snowballing 
process, with those interviewed suggesting further contacts. Although this could be seen to be limiting 
the range of people involved, the method did allow the involvement of those who were interested and 
involved in the care of people with MND and had been involved in the withdrawal of NIV. The interviews 
were undertaken by an experienced interviewer and were either face to face or by telephone, and 
consent was taken beforehand.  
The transcripts of the interviews were coded using a grounded theory approach to identify themes. 
The analysis can also be biased by the researcher, although in these studies there were opportunities 
for other members of the research team, of which I was part, to check and validate the analysis of the 
themes. The replicability of a qualitative study and the transferability to other groups may be 
questioned but the aim in these studies was to obtain a greater, in-depth understanding of the issues 
for this smaller group of participants.  As recruitment continued until there was data saturation, it is 
likely that the results may be transferable to the wider UK population, but they may not be transferable 






This paper, in conjunction with Text 8- Faull et al 2014 has contributed to the knowledge about the 
issues in the withdrawal of assisted ventilation.  This has led to the APM Guidance, described in 5.3.4.  
This Guidance is now available for any professional involved in the withdrawal of ventilatory support 
in MND and has been widely used and overwhelmingly welcomed. 
 




This was an invited editorial to the British Medical Journal Supportive and Palliative Care journal. It is 
a review of the issues involved in the withdrawal of ventilation at the request of the patient with 




The Editorial provides background information on the withdrawal of NIV and summarises the APM 
Guidance. This suggests five standards: Standard 1: that patients are aware that they may stop NIV 
and that this is a legal option; Standard 2: a senior clinician should validate the patient’s request and 
lead on the procedure; Standard 3: withdrawal should be undertaken within a reasonable timeframe 
after the request; Standard 4: symptoms should be anticipated and managed effectively; Standard 5: 
after the death family members should be able to discuss the events. These standards could be au-
dited and it is suggested that after every procedure a data set is submitted and learning shared. The 
Guidance also supports doctors in asking for mentoring from doctors who have experience in the 
area, and the APM would provide details of doctors willing to support others. 
 
5.5.3 Strengths and Limitations 
 
This is a review publication, highlighting an evidence- based document, and so may be considered to 




This Editorial has added to the literature on the withdrawal of ventilatory support at the request of a 
patent with MND.  Together with Text 8 and Text 9 it is now available to provide an evidence base and 






These papers have related to the difficult areas of care of people with neurological disease, and in 
particular MND. These themes have been developed in the literature, with increased awareness of 
the need for advance care planning (Foley et al 2018), the need to discuss end of life issues (Connolly 
et al 2015) and earlier discussion of end of life issues in the disease progression (Eisen et al 2013; 
NICE 2016).  The guidance document to help professionals provide care in the specific situation of NIV 
withdrawal in MND has also been produced (APM 2016). 
 









































The previous chapters have considered the identification of the need and then the evidence for 
palliative care in neurological disease. To enable this evidence to become established within rou-
tine day to day care it is important to enable all involved in care to be aware of the best 
management. The development and use of guidelines can help in this process, with the aim of en-
suring care is evidence based and the quality of care can improve for patients and families.  These 
two papers are based on this approach. 
 
6.2 Consensus review of palliative care for progressive neurological disease – 
Text 11 Oliver et al 2016.  
 
6.2.1 Consensus review 
 
A systematic literature review was undertaken under the auspices of the European Association for 
Palliative Care (EAPC) Taskforce on Neurology and the European Academy of Neurology (EAN) Spe-
cialty Group on Palliative Care. 68 studies were reviewed and Professor Raymond Voltz and I 
assessed the papers and produced a draft list with possible recommendations.  This list was con-
sidered by the wider group and in an iterative process the recommendations were made. The 
initial review was undertaken under the auspices of the European Federation of Neurological Soci-
eties (EFNS) and their grading system was used (Brainin et al 2004). This classified the studies Class 
I to Class IV and the recommendations from Level A (established as effective), Level B (probably 




Seven main areas were developed with recommendations: 
• Early integration of palliative care – which should be considered early in the disease tra-
jectory, depending on the diagnosis 
• Multidisciplinary team approach – of at least three professionals with MDT assessment 
and access to specialist palliative care 





• Symptom management – thorough diagnosis, management and review of symptoms, us-
ing the principles within palliative care and proactive assessment of physical and 
psychosocial issues 
• Carer support – regular assessment of carers, support of carers before and after death. 
Professionals should receive education, support and supervision 
• End of life care – continued and repeated discussion of end of life issues, encouragement 
of open discussion, including wishes to restrict treatment and wish for hastened death, 
recognition of end of life and the dying phase 
• Education and training – training of both specialities with palliative care education for 
neurologists and education in the understanding and management of neurological symp-
toms for palliative care professionals. 
 
6.2.3 Strengths and limitations 
The aim of the EAPC/EAN collaboration was to perform a systematic literature review and develop a 
clear evidence-based guideline.  However, there were limited studies and the quality of the studies was 
poor.  The aim to use randomised controlled trials (RCT) was limited but non-randomised trials and 
observational studies could be considered if there are no relevant RCTs. This may increase the problems 
and in particular imprecision may be unclear (Thornton et al 2013). It has also been suggested that the 
final recommendations may vary with the composition and dynamics within the group assessing the 
studies, and Raine et al found that there was agreement with the research evidence for only 51% of 
192 scenarios she presented to a group of professionals (Raine et al 2004).  There appeared to be 
particular concerns that the results from a specific RCT, with a possible selected population of 
participants, may not always be extrapolated to the general population, which may be more 
heterogeneous and be influenced by multiple other factors (Raine et al 2004). These issues were 
minimised by the involvement of a small group of experts, who were able to collaborate, discuss the 
evidence and come to clear and agreed recommendations. 
There are also concerns that Clinical Guidelines may not always be applied within health services. This 
may be because the guideline has been “science driven” and not “customer driven” and thus seen as 
less relevant. There is a need to develop a programme for implementation to ensure the guideline is 
understood and then used (Grol and Buchan 2006). There is a challenge to ensure Clinical Guidelines 
do become embedded within routine clinical care, which may be encouraged and facilitated by the 





It has been suggested that guidelines may be inaccessible, may have taken a long time in develop-
ment and may be superseded by more recent research, be based on RCTs which may not be so 
relevant in day to day practice and lack user involvement (Chong 2018).  A delay did occur, to some 
extent, as the initial development was under the auspices of the EFNS, which was then amalgamated 
with the European Neurological Society (ENS) in 2014.  The draft paper was ready in 2013 but this 
could not be considered by the EFNS at this time and was only considered by the EAN when this was 
fully functional in 2015.  Thus, there was the possibility that new studies may have been published 




This paper has been cited 87 times in 3 years and has been presented at the congresses of both the 
EAN and EAPC.  It Is available at the EAN website and EAPC and following its publication a Memoran-
dum of Understanding was signed by the Presidents of the EAN and EAPC.  This has established 
collaboration between the two organisations, with educational sessions at each other’s congresses.  
There is very little literature with a clear assessment of the evidence base and this Consensus paper is 
obviously being read and used in the literature. 
 
 
6.3 NICE Guideline on MND – Text 12 Oliver et al 2017 
 
6.3.1 Guideline development 
 
This paper was published following the National Institute for Health and Care Excellence (NICE) 
Guidance on MND. The review questions were developed using the PICO framework – considering the 
patient population, intervention, comparison group and outcome.  These were clearly stated so that 
the clinical literature search can then be undertaken systematically. The study types are clearly defined 
– the aim was to use randomised controlled trials but non-randomised trials and observational studies 
were considered when there were no relevant RCTs.  The data were then synthesised and assessed for 
its quality using the GRADE criteria – the “Grading of Recommendations Assessment, Development and 
Evaluation” (Guyatt et al 2008).  This assessment aimed to consider the risk of bias, indirectness 
(differences in study population, intervention, comparators and outcomes), inconsistency (unexplained 
heterogeneity), imprecision (studies with small numbers of participants), publication bias 
(underestimation or overestimation of the effect with a selective publication of studies).  In this way 




I was Chair of the Guideline Development Group and closely involved in the development of the 
questions, PICOs, analysis of the data and the development of the recommendations. The GDG was 
multidisciplinary and there were patient and carer representatives. Many of the questions had little 
evidence and a consensus recommendation was made following discussion. 
6.3.2 Guideline 
The various areas of care that were assessed, and for which recommendations were made were: 
• recognition of symptoms and referral to neurology 
• information and support at diagnosis- by a Neurologist who is knowledgeable and  
manages MND 
• organization of care – multidisciplinary team approach 
• social care – integrating care at home and ensuring care is constant and co-ordinated 
• provision of equipment to aid activities of daily living – provided appropriately and speed-
ily 
• nutrition – assessment of nutritional needs and coping with swallowing issues 
• communication – enabling communication face to face and by web-based systems 
• muscle problems – enabling mobility and reducing stiffness 
• saliva management – reducing and coping with drooling of saliva 
• cough effectiveness – enabling people to cough if necessary 
• respiratory function – assessment, commencement and monitoring of respiratory 
function and the use of NIV 
• cognitive assessment- to recognize frontal lobe changes and fronto-temporal dementia 
• prognostic factors – specific factors that are related to poor prognosis 
• planning for end of life care – facilitating palliative care and advance care planning,  
supporting patients and families at the end of life and in bereavement.    
         (NICE 2016).  
6.3.3 Strengths and limitations 
The use of the GRADE system did allow the evidence to be assessed effectively. The separation of the 
quality of the evidence and the strength of the recommendation was clear and there is a very explicit 
and transparent system for evaluation (Guyatt et al 2008). This evidence could then be interpreted by 




There may be problems in developing guidelines. Although the GRADE system was developed by a 
widely representative group and is explicit and transparent, certain areas may be misunderstood 
(Guyatt et al 2008). In particular imprecision may be unclear (Thornton et al 2013). It has also been 
suggested that the final recommendations may vary with the composition and dynamics within the 
GDG, and as has been discussed in 6.2.3 Raine et al found that there was agreement with the research 
evidence for only 51% of 192 scenarios she presented to a group of professionals (Raine et al 2004).  
There are also concerns that the results from a specific RCT, with a possible selected population of 
participants, may not always be extrapolated to the general population, which may be more 
heterogeneous and be influenced by multiple other factors (Raine et al 2004). This was minimised by 
the involvement and discussion at the GDG, coming to clear recommendations, which were acceptable 
to all. 
There are also concerns that Clinical guidelines may not always be applied within health services, as 
discussed in 6.2.3.  There was wide involvement of patients and carer representatives in the GDG, a 
process of consultation before publication the Guideline was completed within a period of two years 
and issued within a few weeks of the final deliberations. There is a challenge to ensure Clinical 
Guidelines do become embedded within routine clinical care. The MND Association in England and 
Wales has developed an audit process to encourage and facilitate implementation 
(https://www.mndassociation.org/forprofessionals/transforming-mnd-care/). 
6.3.4 Contribution 
This NICE Guideline has been developed and has been promulgated by the MND Association 
(https://static.mndassociation.org/app/uploads/2017/05/19135522/01A-About-the-NICE-guide-
line-on-MND.pdf). The paper has helped to make the Guideline more available internationally.  
 
The Guideline has been used to develop NICE Quality Standards (NICE 2016) and these have been 
adapted to allow an audit of the care for people with MND (as above).  All areas are encouraged by 
the MND Association to undertake this audit, with the aim of showing areas of good practice and ar-
eas where there is need for improvement. 
 
The Guideline has been widely disseminated, including New Zealand (https://mnd.org.nz/for-profes-
sionals/), Scotland (https://www.care-mnd.org.uk/clinical-professionals/), and Marie Curie 
Foundation (https://www.mariecurie.org.uk/professionals/palliative-care-knowledge-zone/condi-




Society and the Intensive Care society in their own guidelines on ventilatory management (Da-
vidson et al 2016). 
 
The Guideline is widely referenced on many health websites, including Guideline Central 
(https://www.guidelinecentral.com/summaries/motor-neurone-disease-assessment-and-manage-
ment/), Patient info (https://patient.info/doctor/motor-neurone-disease-pro) and the European 
Reference Network EURO-NMD (https://ern-euro-nmd.eu/publication/motor-neurone-disease-
assessment-and-management-2/).   
 
The Guideline has also been used within the NHS England Right Care Progressive Neurological 
Conditions Toolkit (https://www.england.nhs.uk/rightcare/wpcontent/uploads/ sites/40/2019/08 
/progressive-neuro-toolkit.pdf) .  This has considered MND, MS, MSA and PD and aims to provide 
advice and guidance on how commissioners and providers can address the key challenges in com-




These two papers have aimed to increase awareness of the care of people with neurological dis-
ease and provide information, from a clear evidence base, to improve the care of patients and 
their families. They may be considered within a wider literature of evidence-based guidelines 
which have continued to be developed (Andersen et al 2012; Solari et al 2019; Miller et al 2009; 






















7.1 Research in palliative care 
There is a need for research in palliative care, as at present many of the interventions and medications 
used have very limited evidence, at a time when there is an increased move to ensure evidence-based 
care. The complexity of palliative care with very ill patients, often with a short prognosis, raises 
challenges for research, but these need to be addressed to enable the field to develop and for the 
science to be more widely accepted.  
In earlier chapters there has been discussion of the methodology used in each of the papers submitted 
as part of this thesis, including an assessment of their strengths and limitations.  In this chapter wider 
issues of research within palliative care will be considered. 
 
7.2 Issues in undertaking research in palliative care populations 
The needs of patients, and carers, within palliative care are complex and very varied. Physical issues, 
such as the management of pain and other symptoms, are prominent but psychological, social and 
spiritual issues also arise, often with implications both for the care provided and the methodology to 
conduct related research. Moreover, there are complexities in undertaking research as patients have 
progressive disease, may be frail, present multiple rapidly changing symptoms and conditions, and may 
deteriorate, and die, over short periods of time.  There are also issues of recruitment into research 
studies, as healthcare professionals may act as “gatekeepers” and be reluctant to involve very ill 
patients in research, even though the latter may see such involvement as a useful contribution they can 
make to the development of treatment and the understanding of future patients, even if not for 
themselves.   
 
7.3 Ethical issues 
Many ethical issues are raised in palliative care research because of the particular vulnerabilities of 
potential participants (Raus and Sterckx 2018). Consent may become difficult when a participant has 
cognitive loss, with dementia or reduced consciousness near the end of life. Participants may also come 




indication (even a “glimmer of hope”) that an experimental treatment could extend their lives or alter 
the disease progression (Armon 2018).  Their dependence on the caring team may lead to them feeling 
unable to refuse, lest this affects their overall management.  To avoid such issues patients within 
palliative care have sometimes been excluded from studies (Raus and Sterckx 2018; Cassarett 2015). 
Instead, there is a need for careful consideration of the steps needed to enable patients to be involved, 
without them experiencing undue pressure, so that research can proceed in an ethical way. 
 
7.4 Research philosophies and approaches 
The study of knowledge, epistemology, stresses the importance of considering not only what is known 
but how it comes to be known. Research methods stressing the importance of gathering “data” on an 
objective reality would be described as “positivist” and are characterised by the use of empirical, 
quantitative methods. Methods stressing the perceptions of those involved and the subjective 
meanings they ascribe to events would be described as “constructivist” and would typically depend 
more on qualitative approaches (Darlaston-Jones 2007). 
Both approaches are likely to be necessary in gaining a holistic understanding of issues in palliative care, 
given the complex interactions between patients’ more objective symptoms and conditions, their 
broader psychosocial contexts and the subjective meaning of their experiences. A constructivist 
approach may be more helpful in understanding some phenomena, such as the psychosocial and 
spiritual aspects of palliative care, where meaning and emotion are likely to be central to participant 
experience. A positivist approach may enable the objective evaluation of the impact of medication on 
symptoms, although even here there may be underlying subjective aspects – for instance the 
assessment of pain may be influenced by emotional reactions, previous experiences and other issues 
affecting each person uniquely. The use of mixed research methods – quantitative and qualitative - may 
allow both objective knowledge and the information on the underlying experiences to be ascertained, 
allowing inferences to be drawn from the integration of the knowledge arising from both approaches 
(Walshe 2018). 
7.5 Research methodologies 








Consideration of more effective “advertising” of studies and allowing recruitment to be part of the 
routine practice and care within palliative care units have been shown to increase patient involvement 
in research.  It is also important that the culture of an institution allows clinical and research staff time 
so that research is not seen as a burden (Boland et al 2016). 
 
7.5.2 Consent 
A novel approach to consent may also have to be considered, as many patients will not be able to 
consent to participation in a trial at the end of life, due to loss of communication, extreme weakness 
or drowsiness or incapacity. For instance, in the CARiAD study of subcutaneous medication for 
breakthrough symptoms at home patients  the inclusion criteria are of an adult in the last weeks of life 
who is likely to lose the oral route for medication and who has expressed a preference to die at home, 
together with the carer who is willing to give subcutaneous medication (Poolman et al 2019).  The 
patients and family carers will be identified by the professionals and approached with more information 
and the researcher will seek advance consent for both patient and carer, so that all are aware of the 
views on participation in the trial.  If the patient loses capacity to consent later, the assent of a Personal 
Consultee will be sought – usually a family member – or a Nominated Consultee – another health care 
professional – will be asked to give their assent.  In this way very ill patients can be fully included in the 
consent process and involved in the trial (Pollman et al 2019). 
 
7.5.3 Methodology 
The “gold standard” for medical research is generally regarded to be the Randomised Controlled Trial 
(RCT) since this allows the evaluation of the effects of an intervention – benefits and harms - in an 
unbiased manner, with experimental and control groups equally matched at the beginning and all 
parties being blind to whether the participant is having the experimental or the placebo / standard 
care.  It is important to ensure that there is clinical equipoise, with a genuine uncertainty of the 
effectiveness of the intervention, so that there is an initial null hypothesis, that there is no difference 
between the intervention and the control (Freedman 1987). This null hypothesis can then be tested 
within the trial. 
 However, a RCT may lack external validity and generalization of the findings may be limited and the 
planning of a study may take so long that alternative treatment options may be available (Drazen et al 
2017). There are clearly many difficulties in implementing such a design in a palliative care setting, 




Notwithstanding these difficulties, and accepting that RCTs will not always be appropriate to the 
research question, it remains possible to design studies in such a way that these issues can be 
addressed to a considerable extent. 
Other methodologies may be appropriate in the provision of evidence, including observational studies, 
the use of disease registries and practice-based evidence, from the analysis of policies and campaigns 
(Drazen et al 2017).  
 
The Medical Research Council Framework allows the assessment of a complex intervention in a four-
phase process using qualitative and quantitative methodology – as has been described in Section 4.4.3 
and is shown in Table 1 (Campbell et al 2000; Craig et al 2008). This was found to be effective in the 
study in Turin – Text 3 Veronese et al 2016 reported on the qualitative study to ascertain the issues for 
patients and Text 6 Veronese et al 2017 was then a pilot evaluation - see sections 2.4.3 and 4.5.3.  
 
Case reviews allow an assessment of the issues facing patients - as in Text 1 Oliver 1996. There are 
limitations as the group considered may be biased but the information found in such a study can be 
used to help develop further research – Section 2.2.3. When combined with a qualitative assessment 
of care – as in Text 2 Neudert et al 2001 – there is the opportunity to test the effectiveness of an 
intervention to some extent – Section 2.3.3.  
 
Qualitative research, often as part of a mixed methods approach, together with quantitative methods, 
does allow the more complex aspects of care to be evaluated, such as psychosocial or spiritual aspects 
of care.  This has been described above in Text 3 Veronese et al 2016 and Text 9 Phelps et al 2015. This 
approach may provide an indepth approach to the concerns of the participants – whether patients, 
families or professionals. 
 
Single patient (n-of-1) trials have been used – a multicycle, double-blind, controlled crossover trial when 
a patient receives treatment and intervention in a randomised way and only after the trial is the order 
revealed and the participant’s responses found.  Participants all receive the treatment and can assess 
the efficacy for themselves, when the order is revealed (Nikles et al 2011).   It is possible to aggregate 
studies to derive population estimates of effectiveness of the treatment, and the number of patients 
involved will be smaller than in a randomised controlled trial.  
 
Other studies have used a wedge cluster randomised controlled trial approach for the implementation 




randomised sequence.  There is incomplete blinding (because of the nature of the intervention) but 
care is taken to reduce bias by standardisation of data collection.  This approach also allows a qualitative 
element to be introduced (Luckett et al 2018).  
 
7.5.4 Different methodological approaches 
The advantages and limitations of research methods are shown in Table 1. As can be seen there are 
strengths and limitations for all and the complexity of research in palliative care may require a com-
plex methodology. 
 
Thus, there is a need within palliative care to look at new ways of undertaking research, ensuring pa-
tients and families are involved, collaborating between centres and looking at innovative ways of 
undertaking mixed methods research.  RCTs may be possible and a collaborative approach may be 
necessary. The PACE study evaluating a palliative care programme in nursing homes was able to col-
lect large numbers of questionnaires from the staff in the homes in 78 clusters across Europe in 7 
countries in a multi-facility cluster-randomised trial (Van den Block et al 2019).  
 
There are different methodologies to be considered in undertaking research with in palliative care. 
The method used will depend on the question being asked, and a qualitative, quantitative or mixed 
methods approach design may be appropriate. 
 
7.6 Patient participation 
 
There is increasing involvement of patients within the development of research projects – Patient and 
Public Involvement (PPI) (Noble et al 2015).  This is seen as essential to ensure that the patients, fami-
lies and public are all involved in the development of research, which will not only be important to 
enable funding from society but to ensure research is relevant to all concerned. However, there are 
similar concerns to the issues of recruitment of participants in palliative care, as there may be barriers 
to patient participation, because of illness, weakness or remote location, the discussion may be diffi-
cult for patients and families facing the issues of deterioration and dying and death, and there may be 
risk of tokenism (Chambers et al 2019).  The effective involvement of patients and public is worth-
while as this may increase the relevance and quality of research and is often positive for patients - 
giving meaning to life, reassurance, confidence and rewarding (Chamber et al 2019).  There may be 
other methods of undertaking PPI, including research panels (Collins et al 2015) or online systems fa-






7.7 Conclusion   
 
The complexity of palliative care, looking at physical, psycho-social and spiritual aspects of care with 
very ill patients, often with a short prognosis, is a challenge for research.  Innovative ways of under-
taking research, and then ensuring the results and innovations that are found becomes part of an 
evidence-based approach to care, are essential for the development of the specialty, and the care of 






























Methodology Strengths Limitations 
Randomised 
control trial 
Gold standard  
Effectively compares interven-
tion between a control and 
treatment group 
Ideally blinded – so no influ-
ence on management 
Randomisation to remove bias 
Stratification can be used to 
ensure groups have similar 
prognostic factors 
 
Selection bias possible 
Blinding of observers and participants 
may be impossible or difficult 
Study group may not reflect wider popula-
tion and results may not be generalisable 
Power and size may be insufficient  






Phase I Defines the compo-
nents of the study 
Phase II – defines the trial and 
design – acceptability/ feasibil-
ity/ defining control 
intervention / outcomes 
Phase III Main trial – assessing 
methodology – sample size, in-
clusion and exclusion criteria, 
randomisation, challenges of 
complex intervention 
Phase IV – Implementation – 
rate of uptake, stability of in-
tervention, broadening of 
subject groups, adverse effects 
Allows complex intervention 
to be evaluated 
Selection bias in recruitment 
Intervention may not be blinded and sub-
ject to bias 
Commitment to groups may vary, with 
higher drop out in control group 
Control may not be possible – but waiting 
list study used with possible bias in selec-
tion / maintenance of groups 





Rigorous and prospectively de-





Bias in the publications – as non-positive 
results / unfunded / multicentre studies 
may never be published 
Grey literature may be missed 
Lack of RCTs may reduce the range of lit-




Case note  
review 
Notes readily available 
Can be used to assess an initial 




Selection bias in notes used – not all 
available / not all patients in the group 
seen 
Uncontrolled 
Notes not always accurate 
Online survey Anonymous 





Bias in responses – people with stronger 
views may respond more often 
Small response rate 
May not be representative of larger group 
Focus group Views of wider group of peo-
ple ascertained 
Group members may allow 
greater discussion and greater 
depth  
Clear areas discussed with a 
clearly prepared schedule 
 
 
Influence of some participants on others – 
dominance 
Inhibition of some participants to join in 
the discussion 
Coding may be subjective and can vary 
Influence of leader – altering the re-
sponses 
Interview study Opportunity for participants to 
voice their concerns and issues 
Privacy of the response 
Anonymous use of the com-
ments, allowing participants to 
be more open 
 
Influences on participants – of family if 
present, or of interviewer 
Communication / cognition may be af-
fected reducing participants’ responses 
Coding of themes may be subjective 
Participants may be inhibited from re-
sponding or respond in the way they think 
they should 
Survey Relatively easy data collection 
Standardised data collection 
Anonymous 
 
Questions may be misunderstood or mis-
interpreted 
Data may not be uniform due to misunder-
standing 
N-of-1 study Double blind for some inter-
ventions 
Controlled 
Data may not be collected in a standard-




































Smaller numbers of patients 
needed to show effectiveness 











Study looking at the social in-
teraction within an 
environment 
Shadowing of team interac-
tions 
Allows team interactions to be 
observed and studied 
Longer term study 
Presence of the investigator may alter the 
interactions 








The thesis has drawn on a range of my published work over a considerable period of time and has 
been presented within context of the wider literature.  The papers have all been important in the 
development of palliative care for people with neurological disease. The contribution of each pa-
per has been discussed separately and this chapter will aim to summarise the overall contribution 
and the development of the area of care. 
 
 
8.2 Contribution of the research 
 
The role of the papers in the development of neurological palliative care is shown in Figure 1. The 
other relevant literature is shown in the lower section of the Figure.  The research presented has 
aimed to develop the concepts  of care – from assessing the needs of patients and families, con-
sidering the care provided, including the effectiveness of the interventions, the role in the 
complex decision making, the establishment of clear guidelines and the overall development of 
the concepts of palliative care for people with neurological disease.  
 
 
8.3 The contribution to the development of neurological palliative care 
 
Over the last 25 years the role of palliative care in neurology has developed greatly. The papers 
presented in this thesis have been important in showing that people with neurological disease 
have many symptoms and issues, many of which are unmet – sections 2.2.4, 2.3.3, 2.4.4  – and 
this has been shown in many different diseases- section 1.4 (Ng 2018; O’Brien et al 1992; Wiblin et 
al; Edmonds et al 2010; van der Steen et al 2014). 
 
There is increased involvement of palliative care services for neurological patients, building on the 
evidence from the MND survey in 2000 (Text 4 Oliver and Webb 2000).  In Germany an online sur-
vey of neurologists showed 90% reported collaboration with palliative care for patient with ALS, 
MSA and cerebral tumours, although only 12% had received training in palliative care (Golla et al 
2016). A online survey of neurologists and palliative care specialists, organized under the auspices 
of the EAPC and EAN showed widespread collaboration for ALS and cerebral tumours (84% strong 




These online studies may be subject to bias, as completion is more likely by neurologists who 
have involvement or a special interest in palliative care. However, they do provide an insight into 
the issues, which may then be followed up by more comprehensive studies. 
 
The Ne-PAL RCT (Text 6 Veronese et al 2016) was able to show clearly that quality of life and symp-
toms could be improved with palliative care involvement, without an increase in mortality.  There 
have been other studies looking at effectiveness of palliative care, although these have primarily 
focused on short term intervention (Edmonds et al 2010; Hepgul et al 2018) or increasing the ex-
pertise of specialist nurses (Solari et al 2018). In the study we undertook (Text 6 Veronese et al 
2016) a specialist palliative care team was involved and there was clearer evidence of change and 
this approach may have had a greater impact on the patient and family. Further research is 
needed to consider the most effective model of care – see Section 8.4 below. 
 
 
Palliative care services are often involved in the complexity of advanced disease. The papers on 
the ethical issues of the withdrawal of NIV in MND have been very important in raising these com-
plex ethical discussions and issues. The papers (Text 8 Faull et al 2014; Text 9 Phelps et al 2015) 
have shown the pressures and conflicts faced by the professionals involved in the withdrawal of 
treatment and the importance of clear guidelines and the provision of support for those involved.  
This led to the production of the Guidance (APM 2015), which was widely endorsed and was dis-
cussed and summarised in Text 10 Faull and Oliver 2016. 
 
Decision making is often complex for people with neurological disease, who may face loss of com-
munication and cognition (Text 7 Oliver and Turner 2010). This has been shown in studies, with a 
retrospective case series showing that within an inpatient setting the commonest reasons for con-
sultation with palliative care were eliciting goals of care (82% of contact) and that this led to an 
increase in the completion of advance directives (63% to 92%) (Liu et al 2016).  A large study, con-
sidering over 70,000 consultations within 78 services in the USA showed that consultation was 
less often for symptom management, compared to cancer patients, but more often for assistance 
with transition of care at the end of life, and in particular the withdrawal of treatment (Taylor et 
al 2019). A review of the care of people with advanced neurological disease also emphasized the 
complexity of patient care, and particular the challenges in decision making and ethical issues 





The role of palliative care for neurological disease has been emphasised in many guidelines, and 
since 2016 these have referenced the EAN/EAPC Consensus paper (Text 11 Oliver at al 2016).  
Guidelines recommending palliative care involvement include those for ALS (Andersen et al 2012; 
Miller et al 2009; Karam et al 2016; NICE 2016), PD (NICE 2017), glioma (Pace et al 2017) and de-
mentia (van der Steen et al 2014). 
 
8.4 Models of palliative care provision  
 
Thus, the role of palliative care is more accepted, both with neurology and palliative care. There 
are several models of care provision: 
• The MDT approach, with palliative care as a member of this wider MDT.  This has been 
shown to improve length of survival in MND (Aridegbe et al 2013; Rooney et al 2015) but 
there is little research in the care of other diseases. 
• Specialist palliative care involvement from early in the disease progression, with increased 
involvement when there are specific issues, such as symptoms or psychosocial distress or 
complex decision making, collaborating with the specialist MDT which provides ongoing 
care (Bede et al 2011; Oliver 2014) 
• Closer collaboration between neurology and palliative care with increased understanding 
of the roles of both services. This has been shown to be increasing in Germany and across 
Europe (Golla et al 2016; Oliver 2019). Creutzfeldt et al (2016) emphasized the role of the 
neurologists as the “primary palliative care provider”, emphasizing the need for further 
education. 
• In the USA there has been the development of a sub-specialty of Neuro-palliative care.  
Neurologists are able to undertake further training in palliative medicine and provide spe-
cialist care (Robinson et al 2017).  Within the field there has been a move to develop both 
services and research targets for the benefit of patients and families (Creutzfeldt et al 
2018). The training in palliative medicine is limited, and may be only 6 to 12 months, but 
this approach does increase the awareness and expertise within neurological services and 
facilitate the development of a multidisciplinary approach. 
The use of specific models will depend on the patient group, the cultural aspects within the soci-
ety, the experience and skills of the health and social care services and organisational and financial 
aspects, within health provision in different countries.  For instance, in the USA the funding system 
within Medicare restricts “hospice” to the last 6 months of life, and as a result, patients receive 




access hospice and the median hospice involvement is 18 days, with a mean of 86 days (Zucker-
man et al 2016).  The Neuro-palliative care approach allows palliative care provision earlier in the 
disease progression, but with appropriate funding.  The collaborative approach to care will also 
depend on the experience of all involved, and if primary care providers have limited experience 
and skills in palliative care, patients may require specialist services earlier, than if primary care 
provides a wider multidisciplinary approach (Oliver 2018). Cultural issues, both within health and 
social care and wider society, may also influence how palliative care and end of life care are pro-
vided, as in cultures where the discussion of these issues is avoided, patients may be more 
dependent on palliative care from other services, such as neurology and primary care (Clark and 
Phillips 2010).  
Overall, there is an increased awareness of the need of patients with progressive neurological dis-
ease, with palliative care provision earlier in the disease progression, consideration of 
psychosocial issues, preparation for deterioration and dying and caregiver support (Oliver et al 
2016; Oliver 2019).  The system that provides this care may vary from country to country. 
 
8.5 Further research 
There are several areas which would benefit from further research, in order to establish a clear 
evidence base and thus encourage further development of the area: 
 
8.5.1 Symptom management 
 
There is a very limited evidence base for the interventions and medications used in the manage-
ment of symptoms.  It is necessary for assessment of the medication that is routinely used at 
present to test its effectiveness. A RCT approach would allow an assessment that is less open to 
bias.  A N of 1 approach could be used initially to assess the effectiveness of treatments see sec-
tion 7.5 and Table 1. 
 
8.5.2 Education of neurologists and palliative care specialists 
 
Many of the papers in the field discuss the need for education of neurologists in the techniques 
and principles of palliative care and of palliative cares specialists in neurology.  However, there is 
very little literature on the most effective way of undertaking this education which would lead to a 
positive effect on the management and support of patients and families. Different approaches 








8.5.3 Assessment of the multidisciplinary team 
 
There is weak evidence that an MDT approach increases quality of life and length of life for people 
with MND, although these studies have used a historical cohort as the control group and there 
were differences between the groups in the use of interventions and site of onset (Aridegbe et al 
2013). This needs to be studied in other areas, comparing the MDT approach in a RCT or with a 
historical cohort.  The RCT approach would be the ideal approach, but several centres would be 
needed to recruit the numbers of patients needed and the study may need to continue over a 
longer period of time – for MND 1 to 2 years and for other disease, with a longer prognosis, this 
may need to longer. The comparison with a historical cohort may allow a smaller population to be 
studied, but with the risk of increased bias. 
 
An ethnographic approach could be taken to investigate the interactions within the MDT and to 
look at how these interactions between team members affect the care provided.  A disease spe-
cific MDT could be compared to a team where there are no regular meetings, but various 
disciplines are involved in the care of patients in a relatively unco-ordinated way 
 
8.5.4 The effectiveness of palliative care for neurology 
 
There is a need for further trials of the best way for the provision of palliative care for people with 
differing neurological diseases. A RCT may be seen as the ideal method to show the effectiveness 
of an intervention, and for this patient group a Waiting list design may be useful, as discussed in 
4.5.3, 7.3 and Table 1. 
 
The exact nature of the intervention should be clear – with options being a specialist palliative 
care multidisciplinary approach as needed throughout the disease progression, a short-term spe-
cialist approach, for assessment when there are specific issues, or the palliative care approach 
within neurology services.  These different approaches may affect the effectiveness of the inter-








8.5.5 Patient and public involvement 
 
As has been discussed in 7.7 it is important to ensure that there is PPI in the development of fu-
ture studies.  This may enable research to be as relevant as possible for the patients and families, 
ensuring improved recruitment and ensuring research leads to more effective and evidence-based 





The papers presented in this thesis all relate to the many differing issues in the care of people with 
neurological disease.  This is now more widely acknowledged (Lancet Neurology 2017; Borasio 
2013).  My papers have been important in the development of the concepts of neurological pallia-
tive care and have contributed to the continuing debate on the future development of the care for 
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